- Home
- MRM vs GLTO Comparison
MRM vs GLTO Comparison
Compare MRM & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRM
- GLTO
- Stock Information
- Founded
- MRM 2000
- GLTO 2011
- Country
- MRM Japan
- GLTO Denmark
- Employees
- MRM 1101
- GLTO N/A
- Industry
- MRM Other Consumer Services
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- MRM Consumer Discretionary
- GLTO Health Care
- Exchange
- MRM Nasdaq
- GLTO Nasdaq
- Market Cap
- MRM 5.9M
- GLTO 6.5M
- IPO Year
- MRM 2020
- GLTO 2020
- Fundamental
- Price
- MRM $0.73
- GLTO $2.65
- Analyst Decision
- MRM
- GLTO Buy
- Analyst Count
- MRM 0
- GLTO 1
- Target Price
- MRM N/A
- GLTO $10.00
- AVG Volume (30 Days)
- MRM 4.0M
- GLTO 50.2K
- Earning Date
- MRM 01-01-0001
- GLTO 04-28-2025
- Dividend Yield
- MRM N/A
- GLTO N/A
- EPS Growth
- MRM N/A
- GLTO N/A
- EPS
- MRM N/A
- GLTO N/A
- Revenue
- MRM $44,462,062.00
- GLTO N/A
- Revenue This Year
- MRM N/A
- GLTO N/A
- Revenue Next Year
- MRM N/A
- GLTO N/A
- P/E Ratio
- MRM N/A
- GLTO N/A
- Revenue Growth
- MRM 2.80
- GLTO N/A
- 52 Week Low
- MRM $0.34
- GLTO $2.01
- 52 Week High
- MRM $8.39
- GLTO $18.50
- Technical
- Relative Strength Index (RSI)
- MRM 52.73
- GLTO 44.50
- Support Level
- MRM $0.60
- GLTO $2.36
- Resistance Level
- MRM $0.90
- GLTO $2.63
- Average True Range (ATR)
- MRM 0.23
- GLTO 0.30
- MACD
- MRM 0.01
- GLTO 0.06
- Stochastic Oscillator
- MRM 44.69
- GLTO 66.07
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.